Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
NCT ID: NCT02486640
Last Updated: 2023-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
162 participants
OBSERVATIONAL
2015-09-08
2020-01-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
NCT02247310
BAY86-5046 (Betaseron), Non Interventional Studies
NCT02121444
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
NCT03408093
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
NCT03134573
BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program
NCT01233245
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Betaferon
Interferon beta-1b (Betaferon, BAY86-5046)
Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
Betaconnect Autoinjector
Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interferon beta-1b (Betaferon, BAY86-5046)
Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
Betaconnect Autoinjector
Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician
* Patients using or willing to use the BETACONNECT autoinjector for Betaferon application
* Written informed consent
Exclusion Criteria
* Contraindications of Betaferon described in the Summary of Product Characteristics
* Patients participating in any other clinical or non-interventional study, evaluating MS therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wermsdorf, Saxony, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kohler W, Bayer-Gersmann K, Neusser T, Schurks M, Ziemssen T. Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT(R) Autoinjector: A Prospective Observational Cohort Study. Front Neurol. 2021 Feb 24;12:643126. doi: 10.3389/fneur.2021.643126. eCollection 2021.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find results for studies related to Bayer products
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BF1502
Identifier Type: REGISTRY
Identifier Source: secondary_id
18016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.